Myoinositol
Phase 3Small molecule
Myoinositol is one of 69 small molecule programs targeting Growth. It is currently in Phase 3.
4
Indications
11
Total Trials
3
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
79 competitors in Growth
#DrugCompanyPhaseTrials
1Growth Hormone
PfizerPhase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Piqray
NovartisPhase 2
Myoinositol
SSohag University
Phase 3
Acipimox
Boehringer IngelheimPhase 2
Zyloprim
Jazz PharmaceuticalsPreclinical
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Aricept
EisaiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome3 trials
Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome
Completed·—·N/A·NCT01791647·40 enrolled
Metformin2 trials
Outcome1 trial
3 more indications
Ovarian Reserve1 trial
of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve
Not yet recruiting·—·Phase 3·NCT06405204·200 enrolled
Polycystic Ovarian Syndrome1 trial
Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
Not yet recruiting·—·Phase 3·NCT06405243·100 enrolled
Polycystic Ovarian Syndrome (PCOS)1 trial
Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
Completed·—·N/A·NCT07058675·156 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Myoinositol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSohag University